Perspective Therapeutics Inc
Veridion Score
Composite trend over time
Why is CATX moving today?
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CATX.
CATX insider activity
Perspective Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $42K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-17 | 2025-11-13 | Hunt Jonathan Robert | Insider | buy | $2.03 | 11,000 | 59,800 | $22K | SEC Form 4 |
| 2025-11-14 | 2025-11-12 | Williamson Robert F III | Insider | buy | $2.10 | 9,498 | 9,864 | $20K | SEC Form 4 |
CATX contract awards, year to date.
Public federal awards linked to this ticker.
CATX lobbying filings, year to date.
Registered lobbying filings matched to Perspective Therapeutics Inc.